TPN Calculator

Total Parenteral Nutrition (TPN) is intravenous delivery of all nutrients—calories, protein, fats, carbohydrates, electrolytes, vitamins, and minerals—directly into the bloodstream, bypassing the gastrointestinal tract entirely. TPN is indicated when oral or enteral feeding is impossible, inadequate, or contraindicated for extended periods (typically >7-10 days). Primary indications: Short bowel syndrome: Following extensive small intestine resection (<100-150 cm remaining jejunum/ileum), absorption is insufficient. Common causes: Crohn's disease, mesenteric ischemia, trauma, volvulus. Patients may require TPN for months to years while intestine adapts, or permanently if <50 cm remains. Intestinal failure: Severe motility disorders (chronic intestinal pseudo-obstruction, severe gastroparesis), malabsorption syndromes unresponsive to treatment, extensive radiation enteritis, or chronic intestinal ischemia. Prolonged bowel rest: Severe pancreatitis (NPO for 7-14+ days to rest pancreas), high-output enterocutaneous fistulas (>500 mL/day output preventing oral intake), intractable vomiting/diarrhea. Critical illness: Sepsis, multi-organ failure, major burns (>40% body surface), or trauma when enteral feeding fails to meet needs after 7-10 days. Malignancy: Bowel obstruction from cancer (peritoneal carcinomatosis, tumor mass), severe mucositis from chemotherapy/radiation preventing oral intake. Perioperative nutrition: Malnourished patients (>10% weight loss, albumin <3.0 g/dL) before major surgery who cannot tolerate enteral feeding. TPN duration varies: Short-term (1-4 weeks): Post-operative recovery, acute pancreatitis, chemotherapy-induced mucositis. Long-term (months to years): Short bowel syndrome, intestinal failure. Some patients require home TPN (HPN) lifelong. When TPN is NOT appropriate: Functioning GI tract (prefer enteral nutrition—safer, cheaper, preserves gut integrity), expected duration <5-7 days (peripheral nutrition or temporary malnutrition tolerable), poor prognosis with limited life expectancy where comfort is priority, patient/family decline (for home TPN). The decision for TPN involves careful risk-benefit analysis because complications include infection (10-30% develop catheter-related bloodstream infections), metabolic disturbances, liver dysfunction (20-50% develop TPN-associated liver disease long-term), and high cost ($100-300/day hospital TPN, $50-150/day home TPN).

TPN prescription requires precise calculation of energy needs and macronutrient distribution based on patient weight, metabolic state, organ function, and clinical condition. Step 1: Calculate Total Energy Expenditure (TEE): Use Harris-Benedict or Mifflin-St Jeor equation for Basal Energy Expenditure (BEE), then multiply by activity/stress factor. Harris-Benedict: Men: BEE = 66 + (13.7 × weight kg) + (5 × height cm) - (6.8 × age). Women: BEE = 655 + (9.6 × weight kg) + (1.8 × height cm) - (4.7 × age). Stress factors: Hospitalized, not ICU: ×1.2-1.3. Major surgery: ×1.2-1.4. Infection/fever: ×1.2-1.6 (add 13% per °C above normal). Severe sepsis/trauma: ×1.4-1.8. Burns (40-60% BSA): ×1.5-2.0. Example: 70 kg, 170 cm, 50-year-old man, post-operative day 3: BEE = 66 + 959 + 850 - 340 = 1,535 kcal/day. With surgery stress (×1.3): TEE = 1,535 × 1.3 = 2,000 kcal/day target. Step 2: Calculate Protein Requirements: Protein needs vary by clinical status. Standard maintenance: 0.8-1.0 g/kg/day. Hospitalized, stable: 1.0-1.5 g/kg/day. Critically ill/stressed: 1.5-2.0 g/kg/day. Burns, severe trauma: 2.0-2.5 g/kg/day. Renal failure (not on dialysis): 0.6-0.8 g/kg/day (restrict protein). Renal failure on dialysis: 1.2-1.5 g/kg/day (protein losses in dialysate). Hepatic encephalopathy: 0.6-1.0 g/kg/day (restrict to reduce ammonia). Using 70 kg post-op patient: 1.2 g/kg = 84 g protein/day. Amino acid solutions provide 4 kcal/g: 84 g × 4 = 336 kcal from protein. Step 3: Distribute Remaining Non-Protein Calories (NPC): NPC = Total calories - Protein calories = 2,000 - 336 = 1,664 kcal. Distribute between dextrose and lipids: Dextrose (carbohydrates): Typically 50-70% of NPC. Dextrose provides 3.4 kcal/g. Maximum rate: 4-5 mg/kg/min to avoid hyperglycemia. For 70 kg: max ~400-500 g dextrose/day. Target 60% of NPC: 1,664 × 0.6 = 998 kcal ÷ 3.4 = 294 g dextrose/day. Lipids (fat emulsion, typically 20% solution): Remaining 40% of NPC. Lipids provide 9-10 kcal/g (or 2 kcal/mL for 20% emulsion). Target: 1,664 × 0.4 = 666 kcal ÷ 2 = 333 mL 20% lipid/day (~67g fat). Minimum fat: 30-50g/day (prevents essential fatty acid deficiency). Maximum: 2.5 g/kg/day or 60% NPC. Final TPN composition for 70 kg post-op patient: Total calories: 2,000 kcal/day. Protein: 84g (amino acids). Dextrose: 294g. Lipids: 67g (333 mL 20% emulsion). Calorie:Nitrogen ratio: Non-protein calories divided by nitrogen grams (1g nitrogen = 6.25g protein). NPC:N = 1,664 ÷ (84 ÷ 6.25) = 1,664 ÷ 13.4 = 124:1. Optimal ratios: 100-150:1 for anabolism, 80-100:1 for severe stress.

TPN must provide all micronutrients typically obtained from diet since no oral intake occurs. Deficiencies develop rapidly without supplementation. Electrolytes (added to TPN bag): Sodium: 1-2 mEq/kg/day (70-140 mEq/day for 70 kg adult). Adjust based on serum sodium, fluid status. Restrict in heart failure, cirrhosis. Potassium: 1-2 mEq/kg/day (70-140 mEq/day). Critically ill patients with refeeding syndrome may need 2-3 mEq/kg initially. Restrict in renal failure. Chloride: Usually accompanies sodium/potassium as salts. 70-150 mEq/day. Calcium (as calcium gluconate): 10-15 mEq/day (0.15-0.2 mEq/kg). Maximum ~20 mEq/day. Do not exceed compatibility limits with phosphate. Magnesium: 8-24 mEq/day (0.15-0.35 mEq/kg). Higher in refeeding syndrome, malabsorption, diarrhea. Phosphate (as sodium or potassium phosphate): 20-40 mmol/day (0.3-0.6 mmol/kg). Critical in refeeding syndrome (may need 40-80 mmol/day initially). Monitor for hypophosphatemia. Acetate: 40-100 mEq/day. Metabolized to bicarbonate; maintains acid-base balance. Increase in metabolic acidosis. Vitamins (added daily): Fat-soluble vitamins (A, D, E, K): Typically provided as multivitamin preparation (e.g., MVI-12). Vitamin A: 3,300 IU/day. Vitamin D: 200 IU/day (often insufficient; supplement separately if deficient). Vitamin E: 10 IU/day. Vitamin K: 150 mcg/day (or give 10 mg IV/IM weekly separately). Water-soluble vitamins: Thiamine (B1): 6 mg/day (increase to 100-200 mg/day for alcoholics, refeeding syndrome). Riboflavin (B2): 3.6 mg/day. Niacin (B3): 40 mg/day. Pyridoxine (B6): 6 mg/day. Vitamin B12: 5 mcg/day. Folic acid: 600 mcg/day. Pantothenic acid: 15 mg/day. Biotin: 60 mcg/day. Vitamin C: 200 mg/day. Trace elements (added daily or weekly): Zinc: 2.5-5 mg/day standard. Increase to 10-15 mg/day in high GI losses (diarrhea, ostomy, fistula). Copper: 0.3-0.5 mg/day. Omit or reduce in cholestasis (copper accumulates in liver disease). Manganese: 60-100 mcg/day. Reduce or omit in cholestasis (accumulates). Chromium: 10-15 mcg/day. Important for glucose metabolism. Selenium: 20-60 mcg/day. Antioxidant; critical in critical illness. Iron: Not routinely added to TPN (stability/compatibility issues). Give IV iron separately if needed (e.g., iron sucrose 100-200 mg weekly). Monitoring and adjustment: Check electrolytes daily initially, then 2-3× weekly once stable. Monitor magnesium, phosphate daily in refeeding syndrome. Weekly vitamin B12, folate, zinc, selenium. Monthly fat-soluble vitamins. Adjust based on losses (diarrhea, fistula, drains), organ dysfunction, and lab values. Refeeding syndrome prevention: High-risk patients (chronic malnutrition, weight loss >10%, minimal intake 7-10+ days, alcoholism, anorexia) need aggressive micronutrient repletion: Thiamine 200-300 mg IV before TPN, then 100 mg daily × 3-5 days. Phosphate, magnesium, potassium at upper end of range or above. Start TPN at 50-70% of target calories for 2-3 days, advance gradually while monitoring electrolytes every 6-12 hours.

Parenteral nutrition can be delivered via central venous access (CPN/TPN) or peripheral venous access (PPN), with significant differences in composition, duration, and indications. Central Parenteral Nutrition (CPN/TPN): Access: Central venous catheter (CVC) inserted into subclavian, internal jugular, or femoral vein, with tip positioned in superior vena cava or right atrium. Includes peripherally inserted central catheters (PICC lines). Characteristics: Osmolality: Can be >2,000 mOsm/L (hypertonic) because large central veins have high blood flow that rapidly dilutes solution, preventing vascular irritation. Dextrose concentration: Typically 15-35% (high concentration) providing 3.4 kcal/g. A 70% dextrose stock solution is diluted to desired concentration in final TPN bag. Amino acid concentration: 4-7% typically. Total volume: Can be <1,500 mL/day (concentrated formulation) or 2,000-3,000 mL/day, based on fluid needs. Calorie density: 1.0-1.5 kcal/mL allowing full nutrition in limited volume. Duration: Suitable for prolonged use (weeks to months/years). Indications: Expected duration >7-10 days; need for >2,000 kcal/day; fluid restriction requiring concentrated formula; poor peripheral venous access. Complications: Catheter-related bloodstream infection (CRBSI): 1-5 infections per 1,000 catheter-days. Pneumothorax (1-3% during central line insertion). Thrombosis (2-5%). Peripheral Parenteral Nutrition (PPN): Access: Standard peripheral IV in arm or hand veins. Characteristics: Osmolality: Must be <900 mOsm/L (ideally <600-700) to avoid phlebitis/thrombosis of small peripheral veins. Dextrose concentration: Limited to 10-12.5% maximum (lower concentration reduces osmolality). Amino acid concentration: 3-5% typically. Total volume: Large volume required (2,500-4,000 mL/day) to provide adequate calories at low concentration. Calorie density: 0.5-0.7 kcal/mL (dilute). Duration: Short-term only (5-10 days maximum)—peripheral veins become sclerosed/thrombosed from repeated punctures and hypertonic solution. Indications: Expected short duration (<7-10 days); bridge to central access or enteral nutrition; supplementation for patients taking some oral intake; when central access contraindicated. Limitations: Cannot meet full calorie needs (typically provides 1,200-1,800 kcal/day maximum, insufficient for most adults). Requires intact peripheral veins. High fluid volume may be contraindicated (heart failure, renal failure, edema). Frequent IV site changes (every 72-96 hours). Phlebitis/infiltration common. Comparison example for 70 kg patient needing 2,000 kcal: CPN (central): Total volume 2,000 mL. Dextrose 25% (250 g/L × 2L = 500g = 1,700 kcal). Amino acids 5% (50 g/L × 2L = 100g = 400 kcal). Lipids infused separately (250 mL 20% = 500 kcal). Total 2,600 kcal in 2,250 mL. Osmolality ~1,800 mOsm/L. PPN (peripheral): Total volume 3,500 mL. Dextrose 10% (100 g/L × 3.5L = 350g = 1,190 kcal). Amino acids 3.5% (35 g/L × 3.5L = 122.5g = 490 kcal). Lipids 20% (150 mL = 300 kcal). Total 1,980 kcal in 3,650 mL. Osmolality ~650 mOsm/L. PPN requires 60% more volume to deliver same calories. Clinical decision: If TPN expected >7-10 days or patient requires >1,800 kcal with fluid restriction, central access is necessary. PPN is bridge therapy only.

TPN carries significant infectious, metabolic, hepatic, and catheter-related complications requiring vigilant monitoring and prevention strategies. Catheter-Related Bloodstream Infection (CRBSI): Incidence: 1-5 infections per 1,000 catheter-days (hospital), 0.5-2 per 1,000 catheter-days (home TPN). Organisms: Staphylococcus aureus, coagulase-negative staph, Candida species, gram-negative rods. Presentation: Fever, chills within 30-60 minutes of TPN infusion. Positive blood cultures. Prevention: Strict aseptic technique during insertion and dressing changes. Chlorhexidine-impregnated dressings reduce infection 30-50%. Dedicated TPN lumen (do not use for blood draws, medications). Daily line necessity assessment—remove when no longer needed. Treatment: Antibiotic therapy; catheter removal often required (especially S. aureus, Candida). Catheter salvage possible for coag-neg staph with antibiotic lock therapy. Metabolic complications: Hyperglycemia: Most common (30-50% incidence). TPN dextrose overloads insulin capacity. Target blood glucose <180 mg/dL. Requires insulin (usually added to TPN bag: 0.05-0.15 units insulin per gram dextrose, or separate insulin drip/subcutaneous). Monitor glucose every 4-6 hours initially, then daily. Persistent hyperglycemia (>200 mg/dL) increases infection risk 2-3×. Hypoglycemia: If TPN abruptly stopped without tapering. High dextrose rates cause endogenous insulin production; sudden cessation causes rebound hypoglycemia. Prevention: Never abruptly stop TPN; taper over 2-4 hours or provide D10W at same rate for 1-2 hours. Refeeding syndrome: Life-threatening in malnourished patients. Shift from catabolic to anabolic state causes insulin surge → intracellular shift of phosphate, potassium, magnesium → severe hypophosphatemia (<1.5 mg/dL), hypokalemia, hypomagnesemia. Occurs 24-72 hours after TPN initiation. Complications: cardiac arrhythmias, respiratory failure, rhabdomyolysis, seizures. Prevention: Identify high-risk patients (BMI <16, weight loss >15%, minimal intake 7+ days, alcoholism, chronic diuretics). Pre-TPN thiamine 200-300 mg IV. Start TPN at 50-70% of target, advance over 3-5 days. Aggressive electrolyte repletion: phosphate 40-80 mmol/day, potassium 120-200 mEq/day, magnesium 24-48 mEq/day. Monitor electrolytes every 6-12 hours for first 3-5 days. Hypertriglyceridemia: Lipid overload if infusion exceeds clearance capacity. Target triglycerides <400 mg/dL. Reduce or hold lipids if triglycerides >500 mg/dL. Hepatic complications: TPN-associated liver disease (TALD): Occurs in 20-50% of long-term TPN patients (>3-6 months). Spectrum: steatosis → cholestasis → steatohepatitis → cirrhosis. Causes: Excessive dextrose calories (>5 mg/kg/min promotes lipogenesis). Excessive lipid calories (>1 g/kg/day). Choline deficiency. Lack of enteral stimulation (loss of gut hormones). Recurrent infections/inflammation. Presentation: Elevated liver enzymes (ALT, AST, alkaline phosphatase, bilirubin). Progressive jaundice in severe cases. Prevention: Avoid overfeeding (provide only calculated needs, not excess). Cycle TPN (infuse 12-16 hours daily, not continuously 24 hours—allows lipogenesis/oxidation periods). Provide some enteral nutrition if possible (even 10-30 mL/hr prevents complete gut rest). Use soybean oil-based lipids cautiously; consider fish oil-based lipids (Omegaven) which reduce TALD. Ursodeoxycholic acid may help (300 mg PO TID). Monitoring: LFTs weekly initially, then every 1-2 weeks. If enzymes rise >3× baseline, reduce calories 10-20% and reassess. Bone disease: TPN-associated osteopenia/osteoporosis in long-term TPN. Mechanism uncertain (vitamin D metabolism, aluminum contamination in older formulations). Ensure adequate calcium (10-15 mEq/day), vitamin D (800-1,000 IU/day supplementation beyond MVI), monitor bone density annually in long-term TPN patients. Monitoring protocol: Daily (first week): Glucose, electrolytes (Na, K, Cl, CO2), weight, fluid balance. 2-3× weekly (once stable): Glucose, electrolytes, magnesium, phosphate, calcium. Weekly: CBC, liver enzymes (AST, ALT, alk phos, bilirubin), BUN/creatinine, triglycerides, albumin/prealbumin. Monthly (long-term): Vitamins (B12, folate, 25-OH vitamin D), trace elements (zinc, selenium, copper, iron studies). Every 3-6 months (home TPN): Comprehensive metabolic panel, vitamin levels, DEXA bone density (annually), consider liver ultrasound/biopsy if enzymes elevated.

Home Total Parenteral Nutrition (HPN) allows patients with chronic intestinal failure to receive TPN at home rather than hospital, dramatically improving quality of life while reducing costs. Approximately 30,000-40,000 patients in the US receive HPN long-term. Candidacy for HPN: Clinical stability: Medically stable with optimized TPN formula. No active infections or unstable medical conditions. Able to tolerate TPN cycling (infusion over 10-16 hours nightly rather than continuous). Patient/caregiver capability: Patient or caregiver able to learn aseptic technique for catheter care, TPN preparation/connection, pump operation. Adequate manual dexterity and vision. Cognitive ability to manage emergencies (disconnect procedure, troubleshooting alarms). Home environment: Clean space for TPN storage/preparation. Refrigeration for TPN bags (stored at 2-8°C). Electricity for infusion pump. Access to telephone for emergencies. Support system: Home healthcare company providing TPN delivery, supplies, nursing visits, 24/7 on-call support. Insurance coverage (HPN costs $50,000-150,000/year; most covered by Medicare/private insurance but requires ongoing authorization). HPN training and management: Training period: 1-2 weeks inpatient or outpatient training by nutrition support nurse. Learn catheter dressing changes (sterile technique every 7 days or per protocol). Catheter flushing/heparin lock. TPN bag connection/disconnection. Infusion pump operation and troubleshooting. Recognition of complications (infection, occlusion, metabolic). Daily routine: Evening (typical schedule): Remove TPN bag from refrigerator 30-60 minutes before infusion (warm to room temperature). Perform hand hygiene; prepare sterile field. Scrub catheter hub with alcohol/chlorhexidine for 15 seconds. Connect TPN bag to catheter using sterile technique. Program infusion pump (rate, volume, time). Start infusion typically 8 PM-8 AM (12 hours) or 6 PM-10 AM (16 hours). Morning: Flush catheter with saline and heparin. Disconnect TPN; recap catheter. Store infusion pump and supplies. Resume normal daily activities. Cycling benefits: Allows 8-12 hours 'free' from pump/catheter for work, social activities, exercise. Reduces hepatic complications (allows metabolic cycling). Normalizes life compared to continuous 24-hour infusion. HPN monitoring: Home nursing visits: Weekly initially, then monthly once stable. Assess catheter site, change dressing, draw labs, review technique. Laboratory monitoring: Weekly for first month, then every 2-4 weeks. Comprehensive metabolic panel, CBC, liver enzymes, magnesium, phosphate. Monthly vitamin and trace element levels. Physician follow-up: Monthly initially, then every 3-6 months. Review labs, adjust TPN formula, assess for complications. Annual assessments: DEXA scan (bone density), liver imaging (ultrasound or MRI for steatosis/fibrosis), intestinal reevaluation (some patients develop intestinal adaptation over months/years allowing enteral nutrition advancement and TPN weaning). Quality of life (QOL) for long-term HPN: Physical function: Most HPN patients report good to excellent QOL once stable. Able to work (50-70% of HPN patients employed), travel, exercise, maintain social relationships. Cycling TPN overnight crucial for daytime freedom. Fatigue is common (60-70%) but manageable. Psychological impact: Initial adjustment challenging (anxiety about catheter care, body image concerns with permanent catheter, loss of eating pleasure). Long-term adaptation generally positive—patients prefer HPN to chronic malnutrition or repeated hospitalizations. Support groups (Oley Foundation for home IV and enteral nutrition patients) provide peer support and education. Depression/anxiety rates 20-30% (higher than general population)—psychological support important. Social impact: Eating remains social activity even without nutrition (patients can eat small amounts by mouth for pleasure in many cases). Relationships generally maintained; disclosure to employers/friends variable. Travel possible with coordination (portable pumps, TPN delivery to destination, travel insurance). Complications: CRBSI: 0.5-2 infections per 1,000 catheter-days (lower than hospital due to consistent caregiver, clean home environment). Catheter occlusion: 0.3-1 per 1,000 days. Often reversible with thrombolytic therapy (alteplase). Liver disease: 20-40% develop cholestasis/steatosis; 5-10% progress to cirrhosis requiring liver transplantation. Metabolic bone disease: 40-60% develop osteopenia; 10-20% osteoporosis with fractures. Survival: 5-year survival for HPN patients varies by underlying disease: Short bowel syndrome (benign): 80-90%. Crohn's disease: 75-85%. Cancer/radiation enteritis: 30-50%. Motility disorders: 70-80%. Most deaths are from underlying disease or complications (liver failure, sepsis, mesenteric thrombosis), not TPN itself. Cost: HPN costs $50,000-150,000/year (TPN formula $30,000-80,000 + supplies/nursing/monitoring $20,000-70,000). Hospital TPN costs $100,000-300,000/year. HPN provides substantial cost savings while improving QOL. Medicare and most private insurance cover HPN as DME (durable medical equipment) under specific criteria.